SIC
VKTX icon

SJS Investment Consulting’s Viking Therapeutics VKTX Stock Holding History

SJS Investment Consulting’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$118 Buy
+3
New +$97 ﹤0.01% 2580

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

SJS Investment Consulting's VKTX Position: Q2 2026 in Review

SJS Investment Consulting opened a new position in Viking Therapeutics (VKTX) in Q2 2026: 3 shares worth $118. The stake represents ﹤0.01% of the portfolio and ranks #2580 among its holdings.

436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • SJS Investment Consulting held 3 shares of Viking Therapeutics worth $118 as of Q2 2026.
  • Viking Therapeutics was a new SJS Investment Consulting position in Q2 2026.
  • Viking Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2580 holding.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.